摘要
目的比较前列地尔注射液和巴曲酶注射液治疗糖尿病下肢动脉血管病变(lower-extremity arterial disease,LEAD)的疗效和经济性。方法 40例LEAD患者分成前列地尔组和巴曲酶组。巴曲酶组:巴曲酶注射液治疗;前列地尔组:前列地尔注射液治疗。结果前列地尔组和巴曲酶组的显效率、有效率、改善率及总有效率比较,差异无显著性(P>0.05)。两组左足背动脉内径及血流量、右足背动脉内径及血流量在治疗后均明显改善,差异具有显著性(P<0.01或P<0.05),但两组间左足背动脉内径及血流量、右足背动脉内径及血流量比较,差异无显著性(P>0.05)。两组不良反应率差异无显著性(P>0.05)。前列地尔组(总费用:2030元)比巴曲酶组(总费用:4350元)经济实惠。结论前列地尔注射液治疗LEAD疗效可靠,也相对经济实惠。
Objective Comparison of efficacy and economy between alprostadil injection and batroxobin injection treatment of LEAD. Methods Forty cases of LEAD were divided into alprostadil group and batroxobin group. Batroxobin group： batroxobin injection; Alprostadil Group： alprostadil injection. Results The difference of markedly effective, efficient, improving rate and total effective rate of alprostadil group and batroxobin group was not significant （ P 〉 0.05 ）. Diameter and blood flow of the left foot dorsal artery and right foot dorsal artery significantly improved after treatment, the difference was significant （ P 〈 0.01or P 〈 0.05 ）, but the difference of the two groups was not statistically significant （ P 〉 0.05 ） .The difference of adverse reaction rate of the two groups was not significant （ P 〉 0.05 ）. Alprostadil group （ total cost ： 2030 yuan ） was cheaper than batroxobin group （ total cost ： 4350 yuan ）. Conclusion Alprostadil injection treatment of LEAD had good efficacy, and affordable.
出处
《中国现代医生》
2011年第21期84-85,87,共3页
China Modern Doctor
